Tanguler Tolga's Form 4 filing
Alnylam Pharmaceuticals, Inc. (ALNY) · filed Aug 5, 2022
- Accession no.
- 0001735276-22-000067
- Filed
- Aug 5, 2022
- Trade date
- Aug 3-5, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 12 non-derivative transactions. Open-market sales total $770.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tanguler TolgaCIK 0001849458 | Officer (EVP, Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 3, 2022 | Common Stock | AGrant or awardAcquired | +3,629 | $0.00 | $0 | 5,383 | Direct | |
| Aug 3, 2022 | Common Stock | SSaleDisposed | −1,754 | $210.00 | −$368,340 | 3,629 | Direct | |
| Aug 4, 2022 | Common Stock | FTax withholdingDisposed | −1,618 | $189.76 | −$307,031.68 | 2,011 | Direct | |
| Aug 4, 2022 | Common Stock | FTax withholdingDisposed | −170 | $210.50 | −$35,785 | 1,841 | Direct | |
| Aug 5, 2022 | Common Stock | SSaleDisposed | −149 | $215.03F4 | −$32,039.47 | 1,692 | Direct | |
| Aug 5, 2022 | Common Stock | SSaleDisposed | −398 | $216.21F5 | −$86,051.58 | 1,294 | Direct | |
| Aug 5, 2022 | Common Stock | SSaleDisposed | −440 | $217.61F6 | −$95,748.4 | 854 | Direct | |
| Aug 5, 2022 | Common Stock | SSaleDisposed | −541 | $218.71F7 | −$118,322.11 | 313 | Direct | |
| Aug 5, 2022 | Common Stock | SSaleDisposed | −99 | $219.53 | −$21,733.47 | 214 | Direct | |
| Aug 5, 2022 | Common Stock | SSaleDisposed | −105 | $220.95 | −$23,199.75 | 109 | Direct | |
| Aug 5, 2022 | Common Stock | SSaleDisposed | −5 | $224.00 | −$1,120 | 104 | Direct | |
| Aug 5, 2022 | Common Stock | SSaleDisposed | −104 | $225.15 | −$23,415.6 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
Sale prices ranged from $214.86 to $215.13.
Referenced by the price of 1 transaction in Table I.
- F5
Sale prices ranged from $216.01 to $217.01.
Referenced by the price of 1 transaction in Table I.
- F6
Sale prices ranged from $217.10 to $218.10
Referenced by the price of 1 transaction in Table I.
- F7
Sale prices ranged from $218.14 to $219.09.
Referenced by the price of 1 transaction in Table I.